Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.
Kahri
Juhani
J
Department of Internal Medicine, University of Helsinki, Haartmaninkatu 4, 340, 00029, HUS, Finland. juhani.kahri@hus.fi
Valkonen
Miia
M
Bäcklund
Tom
T
Vuoristo
Matti
M
Kivistö
Kari T
KT
D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069059:Atorvastatin; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004357:Drug Synergism; D017809:Fatal Outcome; D015725:Fluconazole / Q000009:adverse effects* / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000209:etiology*
D000935:Antifungal Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D015725:Fluconazole; D000069059:Atorvastatin; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A